Gracell Biotechnologies Inc (DELISTED) (GRCL:DL)
10.25
0.00 (0.00%)
USD |
NASDAQ |
Feb 22, 16:00
Gracell Biotechnologies Research and Development Expense (Quarterly): 12.44M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 12.44M |
| June 30, 2023 | 14.81M |
| March 31, 2023 | 20.09M |
| December 31, 2022 | 15.90M |
| September 30, 2022 | 19.47M |
| June 30, 2022 | 17.71M |
| March 31, 2022 | 19.17M |
| December 31, 2021 | 16.81M |
| Date | Value |
|---|---|
| September 30, 2021 | 13.68M |
| June 30, 2021 | 10.10M |
| March 31, 2021 | 10.08M |
| December 31, 2020 | 9.154M |
| September 30, 2020 | 5.775M |
| June 30, 2020 | 5.753M |
| March 31, 2020 | 3.918M |
| December 31, 2019 | 5.390M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.918M
Minimum
Mar 2020
20.09M
Maximum
Mar 2023
12.52M
Average
13.06M
Median
Research and Development Expense (Quarterly) Benchmarks
| RayzeBio inc (DELISTED) | 18.17M |
| Zai Lab Ltd | 54.64M |
| WuXi Biologics (Cayman) Inc | -- |
| Axonics Inc | 11.06M |
| I-MAB | -- |